Exercise Hormone Irisin Reveals a Complete Molecular Route From Muscle to Brain Protection in Alzheimer’s Disease

Every time we run, swim, or lift weights, our skeletal muscles do far more than burn calories. They release chemical messengers into the bloodstream, and one of these, the hormone irisin, has emerged as one of the most intriguing candidates for explaining why physically active people tend to keep sharper minds as they age. A new review published in the journal Biogerontology assembles the scattered evidence into a single, coherent molecular story, tracing the full pathway by which a signal born in muscle can reach the brain and help defend it against Alzheimer’s disease. The work, led by Xiuyan Duan and Wenfeng Liu of Hunan Normal University in China, argues that the irisin–BDNF axis constitutes a genuine muscle–brain dialogue, one that could be exploited for early prevention and drug development.

The story begins in the muscle fiber itself. During exercise, a transcriptional co-activator called PGC-1α, the master regulator of mitochondrial biogenesis, is activated in skeletal muscle through well-characterized energy-sensing pathways, including AMPK and SIRT1. PGC-1α drives expression of fibronectin domain-containing protein 5, or FNDC5, a membrane protein that is subsequently cleaved to release irisin into the circulation. This PGC-1α/FNDC5/irisin cascade was first described by Bruce Spiegelman’s group in 2012, when irisin was identified as the myokine responsible for driving brown-fat-like thermogenesis in white adipose tissue. Since then, studies have shown that irisin release scales with exercise intensity, occurs independently of age or fitness level, and can be detected in human cerebrospinal fluid by tandem mass spectrometry, a finding that strongly suggests the hormone does not remain confined to the periphery.

How, then, does a peptide secreted by leg muscles influence neurons deep inside the hippocampus? The review highlights recent work pointing to the blood–brain barrier as the critical checkpoint. Endothelial cells lining the brain’s vasculature express integrin receptors, and the αVβ5 integrin in particular has been identified as a binding partner for irisin. Research published in Molecular Neurobiology in 2025 demonstrated that the endothelial αV/β5 integrin signaling pathway plays a critical role in promoting irisin-induced expression of brain-derived neurotrophic factor, or BDNF, in the hippocampus. In other words, circulating irisin appears to engage integrin receptors on the barrier’s endothelial surface, triggering intracellular signaling that ultimately raises BDNF levels in brain tissue. Structural studies have shown that irisin forms a distinctive fibronectin type III dimer with a novel intersubunit beta-sheet, and more recent work indicates that irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90α, adding molecular texture to how the hormone is recognized at the cell surface.

Once inside or at the brain’s doorstep, irisin’s principal downstream effector is BDNF, a neurotrophin long regarded as a cornerstone of synaptic plasticity, learning, and memory. The canonical 2013 study by Christiane Wrann and colleagues showed that exercise induces hippocampal BDNF through the PGC-1α/FNDC5 pathway, and subsequent genetic work established irisin as a critical regulator of cognitive function in mice. BDNF exerts its effects by binding the tropomyosin receptor kinase B, TrkB, a receptor tyrosine kinase that activates intracellular cascades including MAPK/ERK, PI3K/Akt, and PLCγ. Through these pathways, BDNF promotes dendritic growth, spine formation, long-term potentiation, and the activity of CaMKII, the central molecular organizer of synaptic plasticity. It also modulates NMDA receptor-dependent signaling through scaffolding proteins such as Girdin, linking neurotrophin support directly to the glutamatergic machinery of memory.

What makes the new review particularly compelling is its systematic mapping of BDNF’s protective actions onto each of the core pathological hallmarks of Alzheimer’s disease. First, BDNF enhances neuroplasticity, countering the synapse loss that correlates most strongly with cognitive decline. Second, it reduces amyloid-beta burden: exercise and BDNF have been shown to lower amyloid-beta production by enhancing alpha-secretase processing of the amyloid precursor protein, and irisin itself was recently shown to reduce amyloid-beta by inducing the release of the degrading enzyme neprilysin from astrocytes following downregulation of ERK–STAT3 signaling. Third, BDNF signaling restrains tau hyperphosphorylation, in part through modulation of glycogen synthase kinase 3, the kinase whose dysregulation drives pathological tau accumulation. Fourth, the axis dampens neuroinflammation, with aerobic exercise shown to attenuate glial activation and inflammatory signaling in experimental models. In a landmark 2019 study in Nature Medicine, exercise-linked FNDC5/irisin rescued synaptic plasticity and memory defects in Alzheimer’s mouse models, and a 2018 Science paper demonstrated that combined adult neurogenesis and BDNF can mimic exercise effects on cognition in an Alzheimer’s mouse model.

The review does not, however, paint an unconditionally rosy picture. It emphasizes that Alzheimer’s pathology feeds back negatively on the very axis that protects against it. Oxidative stress and mitochondrial dysfunction, both central features of the diseased brain, impair PGC-1α activity, suppress FNDC5 and BDNF expression, and weaken TrkB signaling, thereby creating a vicious cycle in which neurodegeneration erodes the endogenous defense system that would otherwise restrain it. Amyloid-beta oligomers, for instance, interfere with nuclear calcium signals and neuroprotective gene expression in hippocampal neurons, while mitochondrial damage in neural progenitors compromises the energy supply needed to sustain trophic signaling. This bidirectional framing, in which peripheral activation supports central protection but central pathology undermines the axis, transforms the irisin–BDNF system from a simple one-way messenger route into a dynamic feedback circuit whose integrity may itself determine disease trajectory.

From this molecular map, the authors derive a three-tiered translational strategy. Upstream, exercise remains the most physiological intervention, and the review notes that high-intensity exercise elicits greater irisin responses than low-intensity exercise under comparable energy expenditure, informing prescription design. Midstream, the barrier itself becomes a target: engineered blood–brain barrier-crossing peptides, such as those recently described in materials science literature, could enhance delivery of irisin-mimetic or BDNF-boosting agents into the central nervous system. Downstream, small-molecule TrkB agonists offer a way to bypass the hormone entirely. The flavonoid 7,8-dihydroxyflavone, a selective TrkB agonist discovered in 2010, has been shown to prevent synaptic loss and memory deficits in a mouse model of Alzheimer’s disease, and newer agonists such as R13 have demonstrated neuroprotective effects on mitochondrial function in 5×FAD mice. Together, these three intervention points, muscle, barrier, and receptor, define a pipeline for translating the muscle–brain dialogue into clinical practice.

The clinical stakes are enormous. Alzheimer’s disease and related dementias affect tens of millions of people worldwide, and the Global Burden of Disease study projects that prevalence will more than triple by mid-century as populations age. Existing amyloid-targeting therapies provide only modest benefit and come at high cost, which has intensified interest in mechanisms that act upstream or in parallel with amyloid. The irisin–BDNF axis is attractive precisely because it is multi-target: a single physiological signal simultaneously supports plasticity, curbs amyloid, restrains tau pathology, and calms inflammation. It is also supported by converging evidence across disorders, with recent work showing neuroprotective effects of irisin in mouse models of multiple sclerosis, cerebral ischemia, and Parkinson’s disease, suggesting the axis is a general-purpose mediator of exercise-induced brain resilience rather than an Alzheimer’s-specific curiosity.

Important caveats remain. Human irisin biology has historically been complicated by antibody reliability and the low abundance of the hormone, and the precise contribution of peripherally secreted versus centrally produced irisin to hippocampal BDNF induction is still being resolved. Whether boosting the axis in humans will slow cognitive decline in established disease, or only in preclinical stages, awaits intervention trials. Nevertheless, by assembling the complete molecular cascade, from PGC-1α activation in exercising muscle, through FNDC5 cleavage and integrin-mediated barrier engagement, to BDNF release and TrkB signaling in the hippocampus, the review provides a testable framework. It suggests that the old advice to keep moving is not merely generic wellness guidance but a quantifiable molecular prescription, and that pharmacologically reproducing the muscle–brain dialogue may one day offer a preventive strategy against one of medicine’s most feared diseases.

Subject of Research: The irisin–BDNF molecular axis mediating exercise-induced muscle–brain communication and neuroprotection in Alzheimer's disease

Article Title: Irisin-BDNF axis mediates muscle-brain communication: a complete molecular cascade and potential bidirectional feedback from peripheral activation to central protection

Article References: Irisin-BDNF axis mediates muscle-brain communication: a complete molecular cascade and potential bidirectional feedback from peripheral activation to central protection. (n.d.). https://doi.org/10.1007/s10522-026-10510-4

Image Credits: AI Generated

DOI: 10.1007/s10522-026-10510-4

Keywords: irisin, BDNF, Alzheimer's disease, FNDC5, PGC-1α, TrkB, blood-brain barrier, myokine, exercise, neuroprotection, synaptic plasticity, muscle-brain axis